Figure 1From: The Tiotropium Safety and Performance in Respimat® Trial (TIOSPIR®), a large scale, randomized, controlled, parallel-group trial-design and rationaleTIOSPIR® study design. R, randomization; C, Close of study once the planned 1266 events have been reached; SMI, Soft Mist™ Inhaler. For patients who discontinue trial medication before the planned end of the trial, vital status follow-up continues every 12 weeks.Back to article page